Tarsus Pharmaceuticals Inc (TARS) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Tarsus Pharmaceuticals Inc (US:TARS), currently being evaluated. In 2025, Tarsus Pharmaceuticals Inc generated $451.36 Million in revenue and -$22.31 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Tarsus Pharmaceuticals Inc is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $451.36 Million
- Free Cash Flow (2025): -$22.31 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.